AngioDynamics reported fiscal 2027 first-quarter net sales of $80.9 million, up 6.9% year-over-year.
Med Tech revenue increased 13.2% to $39.9 million, marking the company’s eighth consecutive quarter of double-digit Med Tech growth.
Med Device revenue increased 1.4% to $41 million.
Auryon sales increased 14.7% to $18.9 million.
Mechanical Thrombectomy revenue increased 6.7% to $12 million, including 37.4% growth from AlphaVac.
NanoKnife sales increased 29% to $8.3 million, supported by continued demand for prostate procedures.
Gross margin expanded 410 basis points to 59.4%.
Excluding tariff refunds, gross margin would have been 57.8%.
AngioDynamics reported a GAAP net loss of $7.1 million, or $0.17 per share, improving from a $10.9 million loss a year earlier.
Adjusted net loss narrowed to $1.8 million, or $0.04 per share.
Adjusted EBITDA increased to $5 million from $2.2 million.
The company ended the quarter with $34 million in cash and no debt.
AngioDynamics also received FDA Investigational Device Exemption approval for the RELIEF feasibility study evaluating NanoKnife irreversible electroporation for benign prostatic hyperplasia.
For fiscal 2027, the company reiterated revenue guidance of $336 million to $341 million, Med Tech growth of 12% to 15%, adjusted EBITDA of $13 million to $16 million, and adjusted EPS of negative $0.29 to negative $0.24.
KEY QUOTES:
“Our first quarter results reflect the continued, consistent execution we’ve built into this business.”
“Med Tech again led our growth, highlighted by Auryon’s 21st consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.”
Jim Clemmer, President and CEO of AngioDynamics
